Forecast
| Buy |
6 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsIn 2006, VBI Vaccines has already paid €0.62 in dividends. The last payout was in January 2006.
Financials
In the last year, VBI Vaccines had revenue of €7.85M and net profit of -€83.98M
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 7.85M | 678.61% |
| Gross profit | -5.26M | 44.65% |
| Net profit | -83.98M | 36.09% |
| EBITDA | -74.88M | 24.23% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.71M |
Number of shares | 28.68M |
52-week high/low | €1.23 - €0.0523 |
| Dividends | No |
Beta | 2.17 |
P/E ratio | -0.01 |
PEG ratio | 0.00 |
P/B ratio | 0.14 |
P/S ratio | 0.22 |
Company profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
| Name | VBI Vaccines |
| CEO | Jeffery R. Baxter FCMA |
| Headquarters | Cambridge,
ma Canada |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 04/26/2010 |
| Employees | 131 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | VBIV |
Frankfurt | LO91.F |
München | LO91.MU |